Detalles de la búsqueda
1.
Effect of Multiple Sclerosis on Daily Activities, Emotional Well-being, and Relationships: The Global vsMS Survey.
Int J MS Care
; 22(4): 158-164, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32863783
2.
Nursing Management of Gastrointestinal Adverse Events Associated With Delayed-Release Dimethyl Fumarate: A Global Delphi Approach.
J Neurosci Nurs
; 52(2): 72-77, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-32068560
3.
Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.
Mult Scler Relat Disord
; 30: 236-243, 2019 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-30844611
4.
Management Strategies to Facilitate Optimal Outcomes for Patients Treated with Delayed-release Dimethyl Fumarate.
Drug Saf
; 41(4): 347-356, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29218681
5.
Physical activity and cognitive function in adults with multiple sclerosis: an integrative review.
Disabil Rehabil
; 39(19): 1909-1920, 2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27764974
6.
Best Practices in Alemtuzumab Administration: Practical Recommendations for Infusion in Patients With Multiple Sclerosis.
J Infus Nurs
; 39(2): 93-104, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26295502
7.
Prevention and Management of Infusion-Associated Reactions in the Comparison of Alemtuzumab and Rebif(®) Efficacy in Multiple Sclerosis (CARE-MS) Program.
Int J MS Care
; 17(4): 191-8, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26300705
8.
Effects of functional electrical stimulation on gait function and quality of life for people with multiple sclerosis taking dalfampridine.
Int J MS Care
; 17(1): 35-41, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25741225
9.
Efficacy and safety of alemtuzumab in multiple sclerosis and impact on nursing role.
Int J MS Care
; 15(4): 159-68, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-24453779
Resultados
1 -
9
de 9
1
Próxima >
>>